Pharmaceuticals News and Research

RSS

HHS approves first-ever multi-state purchasing pools for Medicaid drug programs

HHS Secretary Tommy G. Thompson today approved plans by five states to pool their collective purchasing power to gain deeper discounts on prescription medicines for their state programs.

22 Apr 2004

Clinical trial of curcumin in people with cystic fibrosis

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced that it is funding a clinical trial of curcumin in people with cystic fibrosis (CF).

22 Apr 2004

SkyePharma delivery technologies for respiratory drugs to feature at two international conferences

SkyePharma PLC has announced that its proprietary delivery technologies for respiratory drugs will be presented later this month at two international conferences, one in the UK and one in America.

22 Apr 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004

FDA approval for drug to treat attention deficit hyperactivity disorder

McNeil Consumer & Specialty Pharmaceuticals has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the use of CONCERTA® (methylphenidate HCl) CII Extended-release Tablets in adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) and to expand labeling to include a 72 mg dosing regimen.

22 Apr 2004

Doctors from the University of Edinburgh and local intensive care units have linked to fight an antibiotic-resistant infection which attacks some hospital patients.

22 Apr 2004

FDA approves new breakthrough Parkinson's drug

FDA has approved Apokyn (apomorphine) as an injectable drug for treating Parkinson's patients during episodes of "hypomobility," so-called "off periods" in which the patient becomes immobile or unable to perform activities of daily living.

21 Apr 2004

Pierre Pettigrew outlines plan of action for health care reforms

Canadians have a "right" to know how long they have to wait to receive medical treatment, Health Minister Pierre Pettigrew said yesterday.

21 Apr 2004

Drug importation a 'counterfeit issue'

A new Pharmaceutical AntiCounterfeiting Insight Report by Lew Kontnik Associates (http://www.LewKontnik.com) calls the current debate over drug importation "a counterfeit" issue.

21 Apr 2004

Altana starts legal action to fight generic drug competition

Altana AG, Germany's fifth-biggest drug maker, is facing a generic challenge from an unnamed competitor to its Protonix ulcer drug. Altana is now readying its patent infringement suit to stave off the generic competition.

21 Apr 2004

New drug is effective at treating patients in the early stages of Parkinson’s

An international team of Parkinson’s disease researchers has shown that a potential new drug is effective at treating patients in the early stages of Parkinson’s and may even slow the progression of the disease.

20 Apr 2004

Pfizer donates £1 million Brighton and Sussex Medical School

Brighton and Sussex Medical School (BSMS) is pleased to announce that it has received a £1 million donation from pharmaceutical company, Pfizer (UK).

20 Apr 2004

Functional genomics provide improved drug discovery

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.

20 Apr 2004

Myriad Genetics advances drug for chemotherapy-induced nausea

Myriad Genetics, Inc. today released new data on MPC-4505, its Neurokinin-1 (NK1) receptor antagonist, a drug candidate for chemotherapy-induced nausea and vomiting (emesis). MPC-4505 is a potent, orally bioavailable, CNS-penetrating, highly selective NK1 antagonist.

20 Apr 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

Australian company set to spearhead drug discovery

An Australian company is set to challenge the boundaries of drug discovery in Australia with the unveiling of the nation's top drug discovery facility by Western Australian Minister for State Development, Clive Brown.

19 Apr 2004

World's largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube

Nuevolution A/S, a privately held drug discovery company today announced that it has generated what it believes to be the world's largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube.

19 Apr 2004

Oral treatment of chronic hepatitis C

Valeant Pharmaceuticals today presented 24-week data from Phase 2 clinical trials of Viramidine, a nucleoside (guanosine) analog Valeant is developing in oral form for the treatment of chronic hepatitis C (HCV) in conjunction with a pegylated interferon.

17 Apr 2004

New and Generic Drug Approvals from FDA

Apidra, Diazepam Injection, Dopram, Fosamax and others

16 Apr 2004

Canadian Prime Minister Paul Martin pledges health care push

Any discussion of health care runs the risk of deteriorating into generalities. So let me be specific: We must reduce wait times. Canadians need to know, Wherever they live, how long it takes to get an MRI, how long it takes to see a doctor, to get needed hip surgery, and how quickly their child will be seen in the emergency ward.

16 Apr 2004